PMID- 18926092
OWN - NLM
STAT- MEDLINE
DCOM- 20081216
LR  - 20211203
IS  - 1540-1405 (Print)
IS  - 1540-1405 (Linking)
VI  - 6 Suppl 5
DP  - 2008 Sep
TI  - NCCN Task Force Report: mTOR inhibition in solid tumors.
PG  - S1-20; quiz S21-2
AB  - The mammalian target of rapamycin (mTOR) protein complex functions as an 
      integration center for various intracellular signaling pathways involving cell 
      cycle progression, proliferation, and angiogenesis. These pathways are frequently 
      dysregulated in cancer, and therefore mTOR inhibition is a potentially important 
      antitumor target. Commercially available mTOR inhibitors include rapamycin (i.e., 
      sirolimus) and temsirolimus. Other agents under investigation include everolimus 
      and deforolimus. mTOR inhibition has been studied in various solid tumors, 
      including breast, gynecologic, gastrointestinal, prostate, lung, and head and 
      neck cancers. Studies have focused on mTOR inhibition as a monotherapy or in 
      combination with other drugs based on the principle that inhibiting as many 
      targets as possible reduces the emergence of drug resistance. Temsirolimus is 
      currently the only mTOR inhibitor that is specifically labeled for treatment of 
      solid tumors. However, preclinical studies and early-phase trials are rapidly 
      evolving. Additionally, research is further defining the complicated mTOR 
      pathways and how they may be disordered in specific malignancies. To address 
      these issues, NCCN convened a task force to review the underlying physiology of 
      mTOR and related cellular pathways, and to review the current status of research 
      of mTOR inhibition in solid tumors.
FAU - Figlin, Robert A
AU  - Figlin RA
FAU - Brown, Elizabeth
AU  - Brown E
FAU - Armstrong, Andrew J
AU  - Armstrong AJ
FAU - Akerley, Wallace
AU  - Akerley W
FAU - Benson, Al B 3rd
AU  - Benson AB 3rd
FAU - Burstein, Harold J
AU  - Burstein HJ
FAU - Ettinger, David S
AU  - Ettinger DS
FAU - Febbo, Phillip G
AU  - Febbo PG
FAU - Fury, Matthew G
AU  - Fury MG
FAU - Hudes, Gary R
AU  - Hudes GR
FAU - Kies, Merrill S
AU  - Kies MS
FAU - Kwak, Eunice L
AU  - Kwak EL
FAU - Morgan, Robert J Jr
AU  - Morgan RJ Jr
FAU - Mortimer, Joanne
AU  - Mortimer J
FAU - Reckamp, Karen
AU  - Reckamp K
FAU - Venook, Alan P
AU  - Venook AP
FAU - Worden, Frank
AU  - Worden F
FAU - Yen, Yun
AU  - Yen Y
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Natl Compr Canc Netw
JT  - Journal of the National Comprehensive Cancer Network : JNCCN
JID - 101162515
RN  - 0 (Protein Kinase Inhibitors)
RN  - 48Z35KB15K (ridaforolimus)
RN  - 624KN6GM2T (temsirolimus)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Clinical Trials as Topic
MH  - Everolimus
MH  - Humans
MH  - Neoplasms/*drug therapy/metabolism/pathology
MH  - Practice Guidelines as Topic
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Protein Kinases/*chemistry/metabolism
MH  - Signal Transduction/*drug effects
MH  - Sirolimus/analogs & derivatives/therapeutic use
MH  - TOR Serine-Threonine Kinases
RF  - 72
EDAT- 2008/11/15 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/11/15 09:00
PHST- 2008/11/15 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/11/15 09:00 [entrez]
PST - ppublish
SO  - J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-20; quiz S21-2.